First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients

2026/04/08 by Denise J. McCulloch, Fareed Khawaja, Frank Tverdek +6 · 1 voice
Agricultural and Biological Sciences · Biochemistry, Genetics and Molecular Biology · Medicine · #Animal Virus Infections Studies #Respiratory viral infections research #Virus-based gene therapy research

paper · doi:10.1093/infdis/jiag213

openalex publication_date 2026/04/08 · openalex created_date 2026/04/20 · openalex updated_date 2026/07/14

Abstract

Respiratory syncytial virus (RSV) infection causes substantial morbidity among hematopoietic cell transplant (HCT) patients and lacks approved therapies. Remdesivir demonstrates antiviral activity in vitro, but data in humans are lacking. We describe 5 HCT recipients with RSV lower respiratory tract infection who were treated with remdesivir with clinical improvement.

Discussions

• First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients ✅ Just Accepted 🔗 https://bit.ly/3QLnTi2 [bsky, 4 points, 0 comments]

Related

• Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry
• Into the Unknown: Practical Remdesivir Restriction in the Era of Widespread SARS-CoV-2 Seropositivity
• Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs
• Remdesivir for the Treatment of Covid-19 — Final Report
• Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series.